XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Reporting - Schedule of Segment Revenue and Operating Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Segment Reporting Information [Line Items]        
Revenues $ 770.4 $ 674.1 $ 2,249.9 $ 2,007.9
Adjusted EBITDA 128.6 105.5 344.4 295.8
Reconciliation of Adjusted EBITDA:        
Income before income taxes 10.9 32.8 72.9 82.3
Net income attributable to non-controlling interests (38.1) (34.6) (118.7) (99.5)
Interest expense, net 50.0 49.8 148.8 144.3
Depreciation and amortization 50.2 28.9 118.7 87.0
Equity-based compensation expense 7.1 4.4 27.1 13.2
Transaction, integration and acquisition costs 31.5 13.0 71.2 38.8
Net loss on disposals, consolidations and deconsolidations 14.7 5.8 21.5 7.5
Litigation settlements and regulatory change impact 1.6 4.2 1.5 13.9
Loss on debt extinguishment 0.0 0.0 5.1 0.0
Undesignated derivative activity 0.0 0.0 0.0 0.6
Other 0.7 1.2 (3.7) 7.7
Transaction and integration costs 29.4 12.8 66.1 37.3
Start-up costs 2.1 0.2 5.1 1.5
(Loss) gain on litigation settlement (0.5) (3.6) 0.8 (8.1)
Other litigation costs 1.1 0.6 2.3 1.4
Additional interest expense for Florida LOP regulation change       4.4
Operating Segments | Surgical Facility Services        
Segment Reporting Information [Line Items]        
Revenues 735.4 657.3 2,158.5 1,956.5
Adjusted EBITDA 149.6 138.6 419.3 384.1
Operating Segments | Ancillary Services        
Segment Reporting Information [Line Items]        
Revenues 35.0 16.8 91.4 51.4
Adjusted EBITDA 0.7 (1.2) (0.6) (2.7)
All other        
Segment Reporting Information [Line Items]        
Adjusted EBITDA $ (21.7) $ (31.9) $ (74.3) $ (85.6)